查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1917876

生物分析检测市场－2026-2031年预测

Bioanalytical Testing Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 149 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计生物分析测试市场将从 2025 年的 40.14 亿美元成长到 2031 年的 96.31 亿美元，复合年增长率为 15.7%。

生物分析检测市场是製药和生命科学产业中重要且不断成长的细分市场，其成长主要得益于其在药物研发和个人化医疗中的关键作用。该市场涵盖对血液、血浆、尿液和组织等生物基质中的药物、代谢物、生物标记和其他分析物的定量检测。其持续成长的动力来自科学、医学和行业趋势的共同作用，包括个人化医疗的兴起、持续的技术创新以及全球不断增长的候选药物和临床试验项目。

市场扩张的关键驱动因素是对个人化医疗和生物标记主导药物研发日益增长的需求。随着治疗策略越来越注重根据患者的基因资讯、疾病特征和预测反应来客製化治疗方法，对先进生物分析的需求变得至关重要。生物分析检测对于识别和检验生物标记、量化标靶结合以及阐明特定患者亚群的药物动力学/动态(PK/PD) 关係至关重要。这种从「一刀切」模式转向精准医疗的转变需要更复杂、更灵敏、更特异的分析方法，从而直接推动了对先进检测服务和专业知识的需求，以支持标靶治疗和伴随诊断。

同时，分析技术的不断进步正在提升生物分析检测的能力和效率。高解析度质谱（HRMS）和超高效液相层析法（UHPLC）等仪器创新，结合先进的配体结合分析平台，不断提高检测的灵敏度、特异性和通量。自动化、机器人技术和先进数据分析的整合简化了工作流程，减少了人为误差，并加快了结果的获取速度。这些技术进步使研究人员能够应对更具挑战性的分子，例如大规模生物製药、细胞和基因疗法以及寡核苷酸，同时产生高品质的数据。这正在推动这些技术在研究和监管检测中得到更广泛的应用，并催生出更具雄心壮志的应用。

此外，全球药物研发活动的持续成长以及慢性病盛行率的不断上升也推动了市场的发展。日益加重的疾病负担，包括癌症、代谢失调和心血管疾病，使得开发新型疗法变得特别迫切。这反过来又推动了大量临床前和临床项目的研发，而每个项目都需要广泛的生物分析支援。从早期候选药物筛检和先导药物最适化到关键性临床试验和上市后监测，检测在整个研发过程中至关重要。临床研究的扩展，包括复杂的研究设计和跨地域的研究，显着增加了检测需求的数量和地理范围，从而为服务供应商提供了稳定的需求基础。

从地理上看，北美在生物分析检测市场占据主导地位。这一优势归功于该地区高度集中的製药和生物技术研发生态系统、高水准的临床试验活动以及对生命科学研发的大量投资。成熟的大规模受託研究机构(CRO)、专业检测实验室和先进学术研究中心网络，创造了紧密联繫且竞争激烈的服务环境。该地区清晰的监管路径和对新型治疗方法的早期应用，进一步巩固了其作为先进生物分析营运中心的领先地位。

儘管成长要素强劲，但市场仍面临诸多限制因素，影响其营运和经济效益。依照监管申报所需的严格标准进行生物分析检测成本高。这些成本主要来自精密的分析设备、高技能人员、昂贵的试剂和参考标准品，以及全球卫生当局强制执行的严格品管和验证流程。此外，取得某些高品质生物样本，特别是针对罕见疾病和特殊患者群体的样本，可能带来后勤和伦理方面的挑战，从而延误调查。另外，应对不断变化的区域监管要求也增加了营运负担和成本，要求检测服务提供者保持高度警觉并不断调整。

竞争格局的特点是大规模全方位服务的合约研究组织 (CRO)、专业分析实验室以及大型製药企业的内部检测能力并存。关键差异化因素包括复杂检测法的技术专长、完善的品质和合规体系、全球企业发展以及端到端的一体化服务交付能力。申办方与试验服务提供者之间建立策略联盟，以充分利用专业知识并管理大型或技术复杂专案的资源，正逐渐成为主流。

总之，生物分析检测市场正与药物发现和开发领域的整体变革同步发展。其发展轨迹与产业向精准医疗、复杂生物製药和加速开发路径的转型紧密契合。未来成长将得益于不断突破可衡量范围和速度极限的技术创新，以及治疗药物研发的持续进步。市场参与企业的成功取决于其能否不断调整自身以支持下一代变革性治疗方法，并在科学卓越性、监管严谨性和营运效率之间取得平衡。

本报告的主要优势：

  • 深入分析：提供对主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、行业垂直领域和其他细分市场。
  • 竞争格局：了解全球主要参与者的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索推动市场的动态因素和关键趋势，以及它们将如何塑造未来的市场发展。
  • 可操作的建议：利用这些见解，在动态环境中做出策略决策，并开拓新的商机和收入来源。
  • 受众广泛：适用于Start-Ups、研究机构、顾问公司、中小企业和大型企业，且经济实惠。

您打算如何使用这份报告？

产业与市场分析、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法规结构及影响、新产品开发、竞争情报

报告范围：

  • 2021年至2025年的历史数据和2026年至2031年的预测数据
  • 成长机会、挑战、供应链前景、法规结构与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 按业务板块和地区（包括国家）分類的收入和预测评估
  • 公司概况（策略、产品、财务资讯、关键发展等）

目录

第一章执行摘要

第二章 市场概览

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策与法规
  • 策略建议

第四章 技术展望

第五章 依分子类型分類的生物分析检测市场

  • 介绍
  • 低分子
  • 聚合物

第六章 依检测类型分類的生物分析检测市场

  • 介绍
  • 药物发现生物分析
  • 非临床生物分析
  • 临床生物分析

第七章 依检体类型分類的生物分析检测市场

  • 介绍
  • 血
  • 尿
  • 唾液
  • 电浆
  • 其他的

第八章 生物分析检测市场（按应用领域划分）

  • 介绍
  • 肿瘤学
  • 神经病学
  • 免疫学
  • 代谢性疾病
  • 感染疾病
  • 其他的

第九章 依最终用户分類的生物分析检测市场

  • 介绍
  • 製药和生物技术公司
  • 合约研究机构
  • 其他的

第十章 生物分析检测市场（按地区划分）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第十一章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 合併、收购、协议和合作
  • 竞争对手仪錶板

第十二章：公司简介

  • Thermo Fisher Scientific Inc.
  • ICON Plc
  • Charles River Laboratories International, Inc
  • IQVIA Holdings, Inc.
  • Syneos Health
  • SGS SA
  • Intertek Group Plc
  • Pace Analytical
  • Eurofins Scientific SE
  • BioPharma Services Inc.

第十三章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061615889

Bioanalytical Testing Market is forecasted to rise at a 15.7% CAGR, reaching USD 9.631 billion in 2031 from USD 4.014 billion in 2025.

The bioanalytical testing market is a critical and expanding component of the pharmaceutical and life sciences industry, underpinned by its essential role in drug development and personalized healthcare. This market encompasses the quantitative measurement of drugs, metabolites, biomarkers, and other analytes within biological matrices such as blood, plasma, urine, and tissues. Its sustained growth is driven by a convergence of scientific, medical, and industrial trends, including the shift towards personalized medicine, continuous technological innovation, and an escalating global pipeline of drug candidates and clinical trials.

A primary driver of market expansion is the accelerating demand for personalized medicine and biomarker-driven drug development. As therapeutic strategies increasingly focus on tailoring treatments to individual patient genetics, disease profiles, and predicted responses, the need for sophisticated bioanalysis becomes paramount. Bioanalytical testing is fundamental for identifying and validating biomarkers, quantifying target engagement, and understanding pharmacokinetic/pharmacodynamic (PK/PD) relationships in specific patient subpopulations. This shift from a one-size-fits-all model to precision medicine necessitates more complex, sensitive, and specific analytical methods, directly increasing the demand for advanced testing services and expertise to support targeted therapies and companion diagnostics.

Parallel to this, relentless advancements in analytical technologies are enhancing the capabilities and efficiency of bioanalytical testing. Innovations in instrumentation, such as high-resolution mass spectrometry (HRMS) and ultra-high-performance liquid chromatography (UHPLC), coupled with advanced ligand-binding assay platforms, are continuously improving assay sensitivity, specificity, and throughput. The integration of automation, robotics, and sophisticated data analytics streamlines workflows, reduces manual error, and accelerates time-to-result. These technological strides enable researchers to tackle more challenging molecules-including large biologics, cell and gene therapies, and oligonucleotides-and generate higher-quality data, thereby encouraging broader adoption and more ambitious applications in both research and regulated studies.

Furthermore, the market is propelled by the persistent rise in global drug development activity and the increasing prevalence of chronic diseases. The growing burden of conditions such as cancer, metabolic disorders, and cardiovascular diseases creates a urgent need for novel therapeutics. This, in turn, fuels a robust pipeline of preclinical and clinical programs, each requiring extensive bioanalytical support. Testing is indispensable across the entire development continuum, from early candidate screening and lead optimization to pivotal clinical trials and post-market monitoring. The expansion of clinical research, including complex trial designs and studies in diverse geographic regions, significantly amplifies the volume and geographic scope of testing requirements, providing a steady demand base for service providers.

Geographically, North America maintains a dominant position in the bioanalytical testing market. This leadership is attributed to the region's concentrated pharmaceutical and biotechnology research ecosystem, a high volume of clinical trial activity, and substantial investment in life sciences R&D. The presence of a mature network of large contract research organizations (CROs), specialized testing laboratories, and advanced academic research centers creates a dense and competitive service landscape. The region's well-defined regulatory pathways and early adoption of novel therapeutic modalities further reinforce its role as a primary hub for sophisticated bioanalytical work.

Despite strong growth drivers, the market faces significant restraints that impact operational and economic feasibility. Conducting bioanalytical testing to the stringent standards required for regulatory submissions involves high costs. These costs are driven by sophisticated instrumentation, highly skilled personnel, expensive reagents and reference standards, and the rigorous quality control and validation processes mandated by global health authorities. Additionally, access to specific and high-quality biological samples, particularly for rare diseases or unique patient populations, can be a logistical and ethical challenge, potentially delaying research. The complexity of navigating evolving regulatory requirements across different regions also adds to the operational burden and cost, demanding constant vigilance and adaptation from testing providers.

The competitive landscape is characterized by a mix of large, full-service CROs, specialized analytical laboratories, and the in-house capabilities of major pharmaceutical firms. Key differentiators include technological expertise in complex modalities, robust quality and compliance systems, global operational footprint, and the ability to provide integrated, end-to-end service offerings. The trend is toward forming strategic partnerships between sponsors and testing providers to leverage specialized expertise and manage capacity for large-scale or technically demanding programs.

In conclusion, the bioanalytical testing market is evolving in lockstep with the broader transformation of drug discovery and development. Its trajectory is firmly aligned with the industry's move towards precision medicine, complex biologics, and accelerated development pathways. Future growth will be sustained by ongoing technological innovation that pushes the boundaries of what can be measured and how quickly, coupled with the relentless pace of therapeutic R&D. Success for market participants will hinge on their ability to balance scientific excellence and regulatory rigor with operational efficiency, while continuously adapting to support the next generation of transformative therapies.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.)

Bioanalytical Testing Market Segmentation

  • By Molecule Type
  • Small Molecule
  • Large Molecule
  • By Analysis Type
  • Discovery Bioanalysis
  • Pre-Clinical Bioanalysis
  • Clinical Bioanalysis
  • By Sample Type
  • Blood
  • Urine
  • Saliva
  • Plasma
  • Others
  • By Application
  • Oncology
  • Neurology
  • Immunology
  • Metabolic Disorder
  • Infectious Disease
  • Others
  • By End-User
  • Pharmaceuticals & Biotech Company
  • Contract Research Organization
  • Others
  • By Geography
  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. BIOANALYTICAL TESTING MARKET BY MOLECULE TYPE

  • 5.1. Introduction
  • 5.2. Small Molecule
  • 5.3. Large Molecule

6. BIOANALYTICAL TESTING MARKET BY ANALYSIS TYPE

  • 6.1. Introduction
  • 6.2. Discovery Bioanalysis
  • 6.3. Pre-Clinical Bioanalysis
  • 6.4. Clinical Bioanalysis

7. BIOANALYTICAL TESTING MARKET BY SAMPLE TYPE

  • 7.1. Introduction
  • 7.2. Blood
  • 7.3. Urine
  • 7.4. Saliva
  • 7.5. Plasma
  • 7.6. Others

8. BIOANALYTICAL TESTING MARKET BY APPLICATION

  • 8.1. Introduction
  • 8.2. Oncology
  • 8.3. Neurology
  • 8.4. Immunology
  • 8.5. Metabolic Disorder
  • 8.6. Infectious Disease
  • 8.7. Others

9. BIOANALYTICAL TESTING MARKET BY END-USER

  • 9.1. Introduction
  • 9.2. Pharmaceuticals & Biotech Company
  • 9.3. Contract Research Organization
  • 9.4. Others

10. BIOANALYTICAL TESTING MARKET BY GEOGRAPHY

  • 10.1. Introduction
  • 10.2. North America
    • 10.2.1. USA
    • 10.2.2. Canada
    • 10.2.3. Mexico
  • 10.3. South America
    • 10.3.1. Brazil
    • 10.3.2. Argentina
    • 10.3.3. Others
  • 10.4. Europe
    • 10.4.1. Germany
    • 10.4.2. France
    • 10.4.3. United Kingdom
    • 10.4.4. Spain
    • 10.4.5. Others
  • 10.5. Middle East and Africa
    • 10.5.1. Saudi Arabia
    • 10.5.2. UAE
    • 10.5.3. Israel
    • 10.5.4. Others
  • 10.6. Asia Pacific
    • 10.6.1. China
    • 10.6.2. India
    • 10.6.3. Japan
    • 10.6.4. South Korea
    • 10.6.5. Indonesia
    • 10.6.6. Thailand
    • 10.6.7. Others

11. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 11.1. Major Players and Strategy Analysis
  • 11.2. Market Share Analysis
  • 11.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 11.4. Competitive Dashboard

12. COMPANY PROFILES

  • 12.1. Thermo Fisher Scientific Inc.
  • 12.2. ICON Plc
  • 12.3. Charles River Laboratories International, Inc
  • 12.4. IQVIA Holdings, Inc.
  • 12.5. Syneos Health
  • 12.6. SGS SA
  • 12.7. Intertek Group Plc
  • 12.8. Pace Analytical
  • 12.9. Eurofins Scientific SE
  • 12.10. BioPharma Services Inc.

13. APPENDIX

  • 13.1. Currency
  • 13.2. Assumptions
  • 13.3. Base and Forecast Years Timeline
  • 13.4. Key Benefits for the Stakeholders
  • 13.5. Research Methodology
  • 13.6. Abbreviations